TES en es it fr

TES Brand names, TES Analogs

TES Brand Names Mixture

  • Bronchyl Syrup (alcohol anhydrous + beechwood creosote + cocillana + eucalyptus + guaiacol oleate + ipecac + lobelia inflata + menthol + myroxylon balsamum + theophylline + white pine)
  • Choledyl Expectorant Elixir (guaifenesin + oxtriphylline)
  • Diuerb tab (oil of fleabane + theophylline + urea)
  • IDM Expectorant tab (guaifenesin + potassium iodide + pyrilamine maleate + theophylline)
  • IDM tab (potassium iodide + pyrilamine maleate + theophylline)
  • PMS-Oxtriphylline Elixir (alcohol anhydrous + oxtriphylline)
  • Pulmo Septol Sirop (beechwood creosote + cocillana + eucalyptus oil + guaiacol + ipecac + lobelia inflata + myroxylon balsamum + theophylline + white pine)
  • Ratio-theo-bronc (guaifenesin + potassium iodide + pyrilamine maleate + theophylline)
  • Tedral tab (l-ephedrine hydrochloride + phenobarbital + theophylline)
  • Theophylline 0.8mg and 5% dextrose inj (dextrose + theophylline)
  • Theophylline 0.8mg/ml in 5% dextrose inj (dextrose + theophylline)
  • Theophylline 1.6mg and 5% dextrose inj (dextrose + theophylline)
  • Theophylline 4mg and 5% dextrose inj (dextrose + theophylline)
  • Theophylline rougier elixir (alcohol anhydrous + theophylline)

TES Chemical_Formula

C7H8N4O2

TES RX_link

http://www.rxlist.com/cgi/generic/theosr.htm

TES fda sheet

TES FDA

TES msds (material safety sheet)

TES MSDS

TES Synthesis Reference

Traube, Ber. 33, (1940)

TES Molecular Weight

180.164 g/mol

TES Melting Point

272 oC

TES H2O Solubility

1-5 g/L

TES State

Solid

TES LogP

-0.773

TES Dosage Forms

Capsule (sustained-release); Elixir; Liquid; Tablet; Tablet (extended-release)

TES Indication

For the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis.

TES Pharmacology

Theophylline, an xanthine derivative chemically similar to caffeine and theobromine, is used to treat asthma and bronchospasm. Theophylline has two distinct actions in the airways of patients with reversible (asthmatic) obstruction; smooth muscle relaxation (i.e., bronchodilation) and suppression of the response of the airways to stimuli (i.e., non-bronchodilator prophylactic effects).

TES Absorption

Theophylline is rapidly and completely absorbed after oral administration in solution or immediate-release solid oral dosage form.

TES side effects and Toxicity

Symptoms of overdose include seizures, arrhythmias, and GI effects.

TES Patient Information

Immediate Release Products

The patient (or parent/care giver) should be instructed to seek medical advice whenever nausea, vomiting, persistent headache, insomnia or rapid heart beat occurs during treatment with theophylline, even if another cause is suspected. The patient should be instructed to contact their clinician if they develop a new illness, especially if accompanied by a persistent fever, if they experience worsening of a chronic illness, if they start or stop smoking cigarettes or marijuana, or if another clinician and a new medication or discontinues a previously prescribed medication. Patients should be instructed to inform all clinicians involved in their care that they are taking theophylline, especially when a medication is being added or deleted from their treatment. Patients should be instructed to not alter the dose, timing of the dose, or frequency of administration without first consulting their clinician. If a dose is missed, the patient should be instructed to take the next dose at the usually scheduled time and to not attempt to make up for the missed dose.

Extended-Release Capsules

This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.

The physician should reinforce the importance of taking only the prescribed dose and the time interval between doses. As with any controlled-release theophylline product, the patient should alert the physician of symptoms occur repeatedly, especially near the end of the dosing interval.

When prescribing administration by the sprinkle method, details of the proper technique should be explained to patient

Patients should be informed of the need to take this drug in the fasting state, and that drug administration should be 1 hour before or 2 hours after meals.

TES Organisms Affected

Humans and other mammals